Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
Anna Maria Di Giacomo(University of Siena), Michele Maio(University of Siena), Luana Calabrò(University of Siena), Riccardo Danielli(University of Siena), Giuseppe Spadola(European Institute of Oncology), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Maurichi(Fondazione IRCCS Istituto Nazionale dei Tumori), Ruggero Ridolfi, Diego Annesi(University of Siena), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), Paola Queirolo, Cristina Maccalli(Azienda Ospedaliera Universitaria Policlinico "G. Martino"), Ester Simeone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Diana Giannarelli(Agostino Gemelli University Polyclinic), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Ester Fonsatti(Istituto di Chimica Biomolecolare), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorenzo Pilla(Université Paris Cité), L. Orgiano(Ospedale Policlinico San Martino)
Cited by 139
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k